Contract & negotiation
The hem/onc contract has pieces most generic physician-contract guides miss: 340B and infusion margin, oncology-specific tail costs, panel-ramp productivity assumptions. These guides focus on the ten levers that move the most dollars, the three exit clauses that bite later, and the red flags that justify slowing down.
Compensation anatomy for hem/onc
Base + wRVU + bonus plus the pieces unique to oncology — infusion margin, 340B economics, drug administration, and research FTE. What goes into the number, and what the number hides.
Exit clauses: noncompete, termination, tail coverage
The three contract terms that bite later, not now. Written in the first attending year, invoked when things go sideways. Here's how to read them.
Red flags in hem/onc offers
A scannable checklist. If three or more of these are in your offer, slow down and get a healthcare employment attorney before signing anything.
The ten levers in a hem/onc contract
Almost everything in an offer is negotiable. These ten levers are the ones most worth the ask — ordered by typical dollar impact over a 5-year window.
Educational content, not legal advice.
Every article here is drafted with guidance and the offer patterns we see across hem/onc practices. These are not reviewed by a healthcare employment attorney. None of it is a substitute for a real attorney review of your specific offer. Before signing anything, have the full employment agreement reviewed by a licensed healthcare employment attorney in the state where you’ll practice.